课题基金 / 基金详情

Hematopoietic Stem Cell Transplantation for Young Adults with SCD - DCC

Hematopoietic Stem Cell Transplantation for Young Adults with SCD - DCC
年轻 SCD 患者的造血干细胞移植 - DCC
批准号:
9532936
负责人:
MARY EAPEN
金额:
$36.08万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-01 至 2020-07-31

项目摘要

项目成果

MARY EAPEN的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(由申请人提供):在儿童时期采取的支持性医疗保健措施成功地预防了镰状细胞病(SCD)的严重感染和许多其他危及生命的并发症,从而提高了成年后的生存率。这在一定程度上改变了SCD的人口统计数据,包括越来越多的患有慢性健康障碍的年轻人。虽然造血细胞移植(HCT)具有治愈潜力,但很少有SCD患者接受HCT治疗,部分原因是这种治疗的毒性。最近,人类白细胞抗原(HLA)分型技术和支持性治疗的进步改善了HCT的结果,特别是在无关供体HCT后。我们已经组织了一个跨学科的移植研究人员和成人镰状细胞提供者小组,以及一个在BMT临床试验网络的临床试验方面经验丰富的daa协调中心,以测试来自HLA相同的同胞或无关骨髓供体的HCT与白消安预处理方案的假设,氟达拉滨和抗胸腺细胞在患有严重SCD的年轻成人中安全有效,两年无事件生存率至少为80%。我们已经测试了招募的可行性和安全性的预处理方案在一个试点研究骨髓移植的成人SCD。我们建议在一项临床试验中检验这一假设,该试验将比较HCT后的结局与接受标准支持治疗的患者的结局,这是血红蛋白疾病的首次此类比较。我们将60例年龄在15-40岁且有合适供体的患者分配至BMT组,同时将120-140例无合适供体的SCD患者入组平行比较队列。我们建议通过以下具体目标来研究严重镰状细胞病成人的HCT:1。确定HCT在患有严重镰状细胞病的年轻人中的安全性和有效性。2.测量供体造血对功能结局和终末器官功能的影响。我们将建立一个长期的随访队列的所有符合条件的患者的目的是未来的研究长期影响HCT的结果在SCD。如果成功,拟议的比较临床试验将是第一个比较HCT和SCD支持治疗的试验,并可能扩大严重SCD成人的治疗机会。
英文摘要
 DESCRIPTION (provided by applicant): Supportive health care measures instituted during childhood successfully prevent serious infections and many other life-threatening complications of sickle cell disease (SCD), resulting in improved survival to adulthood. This has, in part, shifted the demographics of SCD to include a growing proportion of young adults with chronic health impairments. While hematopoietic cell transplantation (HCT) has curative potential, very few individuals with SCD are treated by HCT, due in part to the toxicity of this treatment. Recently, advances in Human Leukocyte Antigen (HLA) typing techniques and supportive care have improved outcomes of HCT, particularly after unrelated donor HCT. We have organized an interdisciplinary group of transplant investigators and adult sickle cell providers as well as a daa coordinating center very experienced in the conduct of clinical trials for the BMT clinical trials network to test the hypothesis that HCT from an HLA-identical sibling or unrelated marrow donor with a conditioning regimen of Busulfan, Fludarabine and anti-thymocyte is safe and effective in young adults with severe SCD with a two year event free survival of at least 80%. We have tested the feasibility of recruitment and safety of the conditioning regimen in a pilot study of BMT in adults with SCD. We propose to test this hypothesis in a clinical trial that it wil compare outcomes after HCT to outcomes observed in those who receive standard supportive care, the first comparison of this kind in hemoglobin disorders. We will assign 60 patients age 15-40 years who have an available suitably matched donor to the BMT arm and will contemporaneously enroll 120-140 SCD who do not an available suitable donor to a parallel comparison cohort. We propose to investigate HCT in adults with severe sickle cell disease by the following specific aims: 1. Determine the safety and efficacy of HCT in young adults with severe sickle cell disease. 2. Measure the impact of donor hematopoiesis on functional outcomes and end-organ function. We will establish a long term follow up cohort of all eligible patients for the purpose of future studies of long term impact of HCT on outcome sin SCD. If successful, the proposed comparative clinical trial would be the first to compare HCT and supportive care for SCD, and could broaden the therapeutic opportunities for adults with severe SCD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Medical College of Wisconsin Physician Scientist Immersion Program
  • 批准号:
    10591714
  • 项目类别:
  • 资助金额:
    $19.51万
  • 财政年份:
    2023
  • 负责人:
    MARY EAPEN
  • 依托单位:
Cure Sickle Cell
  • 批准号:
    10270068
  • 项目类别:
  • 资助金额:
    $987.22万
  • 财政年份:
    2018
  • 负责人:
    MARY EAPEN
  • 依托单位:
海外基金